BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Apogee Technology, Inc. (ATA) Resumes Trading on the OTC Bulletin Board


1/27/2011 8:39:06 AM

NORWOOD, MA--(Marketwire - January 26, 2011) - Apogee Technology (OTCBB: ATCS), a life sciences company focused on the development of vaccine and drug delivery systems, today announced that its shares have resumed trading on the Over The Counter Bulletin Board under the symbol ATCS.OB.

About Apogee Technology, Inc.

Apogee Technology, Inc. was organized as a Delaware corporation in 1987, and is currently focused on the development of advanced vaccine delivery systems, including formulations and devices for immunoadjuvants and ID immunization. It has a unique expertise in the polyphosphazene immunoadjuvant technology. Dr. Alexander Andrianov, its Vice President of Research and Development, is the inventor of the technology and is instrumental in advancing it to clinical trials. Apogee's highly skilled scientific team has a combined 50+ years experience in biotechnology, polymer science, and vaccine delivery and have authored numerous peer-reviewed publications and patents. For more information, please visit our web site at: http://www.apogeebio.com.

PyraDerm™ and Sensilica® are trademarks of Apogee Technology, Inc. All other product names noted herein may be trademarks of their respective holders.

Certain statements made herein that use the words "anticipate," "may," "hope," "estimate," "project," "will," "intend," "plan," "expect," "believe" and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve those related to the use of proceeds from the private placement, the design, development and production efforts of our PyraDerm™ and Sensilica® technologies, known and unknown risks and uncertainties, which could cause the actual results, performance or achievements of the Company to be materially different from those that may be expressed or implied. Please refer to the Company's risk factors as set forth in the Company's filings with the Securities and Exchange Commission, including its report on Form 10-KSB, as amended, for the year ended December 31, 2007, as updated in its quarterly reports on Form 10-Q. The information contained in this press release is believed to be current as of the date of original issue. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company's expectations, except as required by law.


Apogee Investor Contact:
Paul J. Murphy
Chief Financial Officer and Vice President of Finance
Telephone: (781) 551-9450



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES